Is Wall Street Bullish or Bearish on Centene Stock?

With a market cap of $26.2 billion, Centene Corporation (CNC) is a managed care company that provides healthcare programs and services to under-insured families and commercial organizations across the United States. It operates through Medicaid, Medicare, Commercial, and Other segments, offering a wide range of services including health insurance, specialty care, pharmacy services, and behavioral health support.

Shares of the Saint Louis, Missouri-based company have underperformed the broader market over the past 52 weeks. CNC stock has decreased nearly 11% over this time frame, while the broader S&P 500 Index ($SPX) has gained 28.5%. However, the stock has increased 29.1% on a YTD basis, outpacing SPX's 6% return.

In addition, shares of Centene have lagged behind the State Street Health Care Select Sector SPDR ETF's (XLV) 8.3% rise over the past 52 weeks.

Shares of Centene surged nearly 14% on Apr. 28 after the company reported strong Q1 2026 results, delivering $3.37 in adjusted EPS on $49.9 billion revenue, exceeding estimates. The rally was also driven by improved cost efficiency, as its health benefits ratio fell to 87.3%, supported by lower medical costs, reduced flu-related expenses, and a 50 bps drop in Medicaid HBR. Additionally, investor sentiment strengthened after Centene raised its full-year outlook to $187.5 billion - $191.5 billion in revenue and adjusted EPS above $3.40.

For the fiscal year ending in December 2026, analysts expect CNC's adjusted EPS to climb 66.4% year-over-year to $3.46. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing on another occasion.

Among the 20 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, 13 “Holds,” and one “Strong Sell.”

On May 4, TD Cowen raised its price target on Centene to $48 while maintaining a “Hold” rating.

As of writing, the stock is trading above the mean price target of $52.75. The Street-high price target of $68 suggests a 28.4% potential upside.